A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

NCT07743580 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

2000

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

DRUG: Secutrelvir
DRUG: Placebo

Sponsor

Shionogi